Dublin, April 01, 2022 (GLOBE NEWSWIRE) -- The "Global Acral Lentiginous Melanoma Drugs Market 2021-2027" report has been added to ResearchAndMarkets.com's offering.
The global acral lentiginous melanoma drugs market is anticipated to grow at a considerable CAGR during the forecast period. Melanoma that develops on the palms or soles is known as acral lentiginous melanoma. Acral lentiginous melanoma begins as a flat area of discoloured skin that progressively grows in size. According to the National Center for Biotechnology Information, acute lentiginous melanoma accounts for around 2%-3% of all melanomas
The global acral lentiginous melanoma drugs market is segmented based on therapy into chemotherapy, targeted therapy, and immune therapy. Geographically, the global acral lentiginous melanoma drugs market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World.
Market Segmentation
- Global Acral Lentiginous Melanoma Drugs Market Research and Analysis by Therapy
The Report Covers
- Comprehensive research methodology of the global acral lentiginous melanoma drugs market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global acral lentiginous melanoma drugs market.
- Insights about market determinants that are stimulating the global acral lentiginous melanoma drugs market.
- Detailed and extensive market segments with the regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Key Topics Covered:
1. Report Summary
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Conclusion
3. Market Determinants
3.1. Motivators
3.2. Restraints
3.3. Opportunities
4. Market Segmentation
4.1. Global Acral Lentiginous Melanoma Drugs Market by Therapy
4.1.1. Chemotherapy
4.1.2. Targetted Therapy
4.1.3. Immuno Therapy
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AbbVie Inc
6.2. Amgen
6.3. Bristol-Myers Squibb
6.4. Celgene
6.5. Eli Lilly & Co.
6.6. Johnson & Johnson
For more information about this report visit https://www.researchandmarkets.com/r/j6d1w1
